This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pletz, M. W.
Right arrow Articles by Lode, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pletz, M. W.
Right arrow Articles by Lode, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2003, p. 2158-2160, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2158-2160.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Effect of Calcium Carbonate on Bioavailability of Orally Administered Gemifloxacin

M. W. Pletz,1 P. Petzold,1 A. Allen,2 O. Burkhardt,1 and H. Lode1*

Department of Chest and Infectious Diseases, City Hospital E. v. Behring, Free University of Berlin, Germany,1 Clinical Pharmacokinetics Department, GlaxoSmithKline Laboratories, Greenford, Middlesex, United Kingdom2

Received 17 January 2003/ Returned for modification 3 March 2003/ Accepted 1 April 2003

We investigated the effect of calcium carbonate on the oral bioavailability of gemifloxacin. Gemifloxacin was administered alone, 2 h before, simultaneously, or 2 h after calcium carbonate in 16 volunteers. Data for 320 mg of gemifloxacin alone were as follows: maximum concentration of drug in serum (Cmax),13 µg/ml; half-life, 7.33 h; and area under the concentration-time curve from 0 h to infinity (AUC{infty}), 6.79 µg · h/ml. Only simultaneous coadministration of calcium carbonate reduced Cmax (-17%) and AUC{infty} (-21%) significantly.

* Corresponding author. Mailing address: Department of Chest and Infectious Diseases, Zentralklinik E. v. Behring/Dept. Lungenklinik Heckeskorn (Academic Teaching Hospital of FU Berlin), Zum Heckeshorn 33, 14109 Berlin. Phone: 49 30 80022222. Fax: 49 30 80022623. E-mail: haloheck{at}zedat.fu-berlin.de.

Antimicrobial Agents and Chemotherapy, July 2003, p. 2158-2160, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2158-2160.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»